◆英語タイトル:Proton Pump Inhibitors Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
◆発行会社(リサーチ会社):Mordor Intelligence
Single User(1名利用)USD4,250 ⇒換算¥484,500見積依頼/購入/質問フォーム
Team User(5名利用)USD4,750 ⇒換算¥541,500見積依頼/購入/質問フォーム
Corporate License(法人利用)USD7,500 ⇒換算¥855,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はMordor Intelligence社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Mordor Intelligence社の概要はこちらでご確認いただけます。


The proton pump inhibitors market was valued at USD 2,750 million in 2020 and is anticipated to reach USD 3,585 million in 2026, by registering a CAGR of nearly 4.5 % during the forecast period.

Many researchers have found that proton pump inhibitors have increased the risk of COVID-19 in patients taking these medications. The researchers of the American Journal of Gastroenterology, in 2020, conducted a research in which more than 53,000 people taking Proton Pump Inhibitors participated, out of these 3,386 said they had tested positive for COVID-19. This factor is expected to affect market growth as the patient undergoing PPI therapy are advised to consume less medication and avoid these medications unless it is emergent. Thus a negative impact because of COVID-19 in this market can be observed.

Proton Pump inhibitors are gold standard medication for gastroesophageal reflux disease (GERD), the increasing prevalence of GERD and the rising acceptance of novel drug delivery systems are the two most prominent factors driving the growth of the market.

GERD has become a common lifestyle problem among the population in developed and developing regions. Also, for instance, the United States National Library of Medicine (NCBI) published a report in October 2018, which stated that approximately, 8.8–25.9% population in Europe, 2.5–7.8% in East Asia, 18.1–27.8% in North America, 11.6% in Australia, and 23.0% in South America had Gastroesophageal Reflux Disease (GERD) in that year. Also, according to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, globally there were 9283 (8189 to 10 400) cases per 100 000 population in 2017 and 709 million (626 to 795) population of the world reported GERD in 2017.

According to the Mayo Foundation for Medical Education and Research, risk factors such as aging, obesity, delayed stomach emptying, changing lifestyle associated with smoking, consumption of alcohol, coffee, fatty, and fried foods are the major reason for the occurrence of GERD. World Population Ageing Report, 2019 by Department of Economic and Social Affairs, United Nation states that in 2019, there were 703 million persons aged 65 years or over in the global population and this number is positioned to double 1.5 billion in 2050. In addition, players in this market are developing novel products and coming up with new product launches to leverage market opportunities. For instance, in May 2019, Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners signed a collaborative agreement to launch Phathom Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. Hence, the increasing prevalence of GERD, along with the growing risk factor population, is likely to increase the demand for proton pump inhibitors, which in turn, is expected to drive the market. Also, the increasing shift from prescription to OTC drugs is also one of the driving the proton pump inhibitors market.

However, the increasing use of generic products in the market and side effects associated with the drugs are the factors that can hamper the market growth.

Key Market Trends

The Esomeprazole Segment is Expected to Account for Significant Share Over the Forecast Period

As per the financial results released by AstraZeneca, it was reported that the net sale of Nexium (Esomeprazole) declined in Q1 of 2020. The reported sale of Q1 2020 was found to be USD 338 million as compared to USD 363 million in Q1 in 2019 due to the emergence of COVID-19 and lockdown guidelines and due to the guidelines by the various regulatory bodies to avoid the treatment of proton pump inhibitors. However, later the sales started resuming and in Q4 the net sale of Nexium amounted to USD 401 million.

Esomeprazole is considered one of the leading revenue-generating drugs in the market, and it is mostly indicated to treat the symptoms of GERD, heartburn, and other disorders involving excessive stomach acids. The drug was being sold as a prescriptive drug till before March 28, 2014, the date when FDA approved it as an OTC drug. The shift from being a prescription-only drug to being sold as an over the counter (OTC) drug is likely to be a major driving force for the sales of the drug in the near future.

In addition, major market players are focused on R&D and market expansion activities, to bring new and reliable formulations to the market. For instance, in July 2020, Cadila Pharmaceuticals launched esomeprazole tablets for the treatment of hyperacidity and drug-induced gastritis under the brand name, Esiloc, in India. Thus, owing to all the above-mentioned factors the Esomeprazole segment is expected to achieve high growth rates.

North America is Expected to Account for Largest Share of the Market

North America currently dominates the market share in the proton pump inhibitors market and is anticipated to show a similar trend over the forecast period, without significant fluctuations. There is a rising burden of GERD in the United States, Canada, and Mexico due to shifting toward an unhealthy lifestyle. According to a study by Lancet Gastroenterology and Hepatology in 2017, the prevalence of GERD in the United States was highest with more than 11,00 cases per 100,000 population. Also, according to a report published by the Journal of Neurogastroenterology and Motility at NCBI in 2018, approximately 20% of the adults and 18-27.8% of the United States population reported the problem of GERD.

Proton pump inhibitors are one of the most widely prescribed drugs, and an increased PPI use has been observed in the US ambulatory settings for the last few years. Furthermore, many firms are spending heavily on promoting their brands. The widespread use of these PPI has also gained attention from the American Board of Internal Medicine, as a result, the board conducted a campaign to promote the appropriate use of PPIs. Moreover, product launches in a generic category are also expected to impact the market. For instance, in January 2019, Dr. Reddy’s launched generic omeprazole delayed-release tablets for the treatment of heartburn in the United States. Hence, rising expenditure in healthcare, change in lifestyle, and increasing geographic footprints of the player in this region is expected to boost the market growth.

North America is one of the worst affected regions by the ongoing COVID-19 pandemic. The growth of the proton pump inhibitor market is expected to slow down to some extent because of the restriction in the import of several non-essential drugs by the United States Food and Drug Administration and other regulatory bodies in the country.

Competitive Landscape

The proton pump inhibitors market is a fragmented one, owing to the presence of various players in the market. The market players are focusing on acquiring the market share by focusing on aggressive advertisements and awareness programs among the patients. The major key players in the market include AstraZeneca, Bayer AG, Cadila Pharmaceuticals, GlaxoSmithKline PLC, Johnson & Johnson, and Pfizer.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support


1.1 Study Assumptions and Market Definition
1.2 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Gastroesophageal Reflux Disease (GERD)
4.2.2 Rising Acceptance of Novel Drug Delivery Systems
4.3 Market Restraints
4.3.1 Increasing Use of Generic Products
4.3.2 Side Effects Related to Proton Pump Inhibitors
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Drug Type
5.1.1 OTC (Over-the-Counter) Drugs Omeprazole Lansoprazole Esomeprazole Other OTC Drugs
5.1.2 Prescription Drugs Rabeprazole Dexlansoprazole Pantoprazole Other Prescription Drugs
5.2 Geography
5.2.1 North America United States (By Drug Type) Canada (By Drug Type) Mexico (By Drug Type)
5.2.2 Europe Germany (By Drug Type) United Kingdom (By Drug Type) France (By Drug Type) Italy (By Drug Type) Spain (By Drug Type) Rest of Europe (By Drug Type)
5.2.3 Asia-Pacific China (By Drug Type) Japan (By Drug Type) India (By Drug Type) Australia (By Drug Type) South Korea (By Drug Type) Rest of Asia-Pacific (By Drug Type)
5.2.4 Middle East and Africa GCC (By Drug Type) South Africa (By Drug Type) Rest of Middle-East and Africa (By Drug Type)
5.2.5 South America Brazil (By Drug Type) Argentina (By Drug Type) Rest of South America (By Drug Type)

6.1 Company Profiles
6.1.1 AstraZeneca
6.1.2 Bayer AG
6.1.3 Cadila Pharmaceuticals
6.1.4 Eli Lilly and Company
6.1.5 Eisai Inc.
6.1.6 GlaxoSmithKline PLC
6.1.7 Johnson & Johnson
6.1.8 Pfizer Inc.
6.1.9 Santarus Inc.
6.1.10 Takeda Pharmaceuticals
6.1.11 Eisai Pharmaceuticals India Pvt. Ltd